Advertisement

Archives of Orthopaedic and Trauma Surgery

, Volume 136, Issue 12, pp 1723–1732 | Cite as

Leukocyte-poor platelet-rich plasma is more effective than the conventional therapy with acetaminophen for the treatment of early knee osteoarthritis

  • Mario Simental-Mendía
  • José F. Vílchez-Cavazos
  • Víctor M. Peña-Martínez
  • Salvador Said-Fernández
  • Jorge Lara-Arias
  • Herminia Guadalupe Martínez-RodríguezEmail author
Arthroscopy and Sports Medicine

Abstract

Introduction

Knee osteoarthritis (OA) is a degenerative and progressive articular cartilage disease. Infiltration of autologous platelet-rich plasma (PRP) has been proposed as a therapeutic alternative due to the content of biologically active cytokines in PRP. We aimed to compare the clinical response of acetaminophen and intra-articular leukocyte-poor PRP (LP-PRP) in early knee OA.

Materials and methods

A total of 65 patients with clinically and radiographically documented knee OA (grade 1–2) were analyzed. Patients were randomized into two groups: 32 were treated with acetaminophen (500 mg/8 h) over 6 weeks, and 33 received three intra-articular injections of autologous LP-PRP (once every 2 weeks). All patients were evaluated by the Visual Analogue Scale (VAS), the Western Ontario and McMaster Universities (WOMAC) score, and the SF-12 health survey at baseline and 6, 12, and 24 weeks of follow-up. All LP-PRP preparations were analyzed for the platelet, leukocyte, IL-1ra, and TGF-β concentrations.

Results

The decrease in the VAS pain level in the LP-PRP group was greater than that in the acetaminophen group (p < 0.05). Patients treated with LP-PRP showed a sustained improvement in knee function at week 24 (p < 0.01). The SF-12 results only indicated an improvement in quality-of-life in the LP-PRP group at 6, 12, and 24 weeks of follow-up (p < 0.01). Both IL-1ra and TGF-β were detected in the LP-PRP samples (313.8 ± 231.6 and 21,183.8 ± 8556.3 pg/mL, respectively).

Conclusions

Treatment with LP-PRP injections resulted in a significantly better clinical outcome than did treatment with acetaminophen, with sustained lower EVA and WOMAC scores and improvement in quality-of-life (higher SF-12 score). Therapy with LP-PRP may positively modify the inflammatory joint environment by counteracting IL-1β action.

Keywords

Leukocyte-poor platelet-rich plasma Acetaminophen Osteoarthritis Intra-articular infiltration 

Notes

Acknowledgments

M. Simental-Mendía received a fellowship from the Consejo Nacional de Ciencia y Tecnología (CONACYT), México.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Johnson VL, Hunter DJ (2014) The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 28:5–15. doi: 10.1016/j.berh.2014.01.004 CrossRefPubMedGoogle Scholar
  2. 2.
    Nelson AE, Allen KD, Golightly YM et al (2014) A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the US bone and joint initiative. Semin Arthritis Rheum 43:701–712. doi: 10.1016/j.semarthrit.2013.11.012 CrossRefPubMedGoogle Scholar
  3. 3.
    Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64:465–474. doi: 10.1002/acr.21596 CrossRefGoogle Scholar
  4. 4.
    Flood J (2010) The role of acetaminophen in the treatment of osteoarthritis. Am J Manag Care 16:S48–S54PubMedGoogle Scholar
  5. 5.
    Reid MC, Shengelia R, Parker SJ (2012) Pharmacologic management of osteoarthritis-related pain in older adults. Am J Nurs 112:S38–S43. doi: 10.1097/01.NAJ.0000412650.02926.e3 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    McAlindon TEE, Bannuru RRR, Sullivan MC et al (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil 22:363–388. doi: 10.1016/j.joca.2014.01.003 CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:476–499. doi: 10.1016/j.joca.2010.01.013 CrossRefPubMedGoogle Scholar
  8. 8.
    Raeissadat SA, Rayegani SM, Babaee M, Ghorbani E (2013) The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Res Treat 2013:1–7. doi: 10.1155/2013/165967 CrossRefGoogle Scholar
  9. 9.
    Blasioli DJ, Kaplan DL (2014) The roles of catabolic factors in the development of osteoarthritis. Tissue Eng Part B Rev 20:355–363. doi: 10.1089/ten.teb.2013.0377 CrossRefPubMedGoogle Scholar
  10. 10.
    Kavadar G, Demircioglu DT, Celik MY, Emre TY (2015) Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: a randomized prospective study. J Phys Ther Sci 27:3863–3867. doi: 10.1589/jpts.27.3863 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dold AP, Zywiel MG, Taylor DW et al (2014) Platelet-rich plasma in the management of articular cartilage pathology: a systematic review. Clin J Sport Med 24:31–43. doi: 10.1097/01.jsm.0000432855.85143.e5 CrossRefPubMedGoogle Scholar
  12. 12.
    Kon E, Filardo G, Di Matteo B, Marcacci M (2013) PRP for the treatment of cartilage pathology. Open Orthop J 7:120–128. doi: 10.2174/1874325001307010120 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fernandes JC, Martel-Pelletier J, Pelletier J-P (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237–246. doi: 10.3233/BIR-14016 PubMedGoogle Scholar
  14. 14.
    van Buul GM, Koevoet WLM, Kops N et al (2011) Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 39:2362–2370. doi: 10.1177/0363546511419278 CrossRefPubMedGoogle Scholar
  15. 15.
    Pereira C, Scaranari M, Benelli R et al (2013) Dual effect of platelet lysate on human articular cartilage: a maintenance of chondrogenic potential and a transient pro-inflammatory activity followed by an inflammation resolution. Tissue Eng Part A 19:1476–1488. doi: 10.1089/ten.TEA.2012.0225 CrossRefPubMedGoogle Scholar
  16. 16.
    Sundman EA, Cole BJ, Karas V et al (2014) The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med 42:35–41. doi: 10.1177/0363546513507766 CrossRefPubMedGoogle Scholar
  17. 17.
    Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB (2013) Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol 25:136–144. doi: 10.1097/BOR.0b013e32835a9381 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Civinini R, Nistri L, Martini C et al (2013) Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab 10:26–29. doi: 10.11138/ccmbm/2013.10.1.026 PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kijowski R, Blankenbaker D, Stanton P et al (2006) Arthroscopic validation of radiographic grading scales of osteoarthritis of the tibiofemoral joint. Am J Roentgenol 187:794–799. doi: 10.2214/AJR.05.1123 CrossRefGoogle Scholar
  20. 20.
    Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. Arthritis Care Res (Hoboken) 63:S240–S252. doi: 10.1002/acr.20543 CrossRefGoogle Scholar
  21. 21.
    Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
  22. 22.
    Gandhi SK, Salmon JW, Zhao SZ et al (2001) Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clin Ther 23:1080–1098. doi: 10.1016/S0149-2918(01)80093-X CrossRefPubMedGoogle Scholar
  23. 23.
    Wang-Saegusa A, Cugat R, Ares O et al (2011) Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg 131:311–317. doi: 10.1007/s00402-010-1167-3 CrossRefPubMedGoogle Scholar
  24. 24.
    Dohan Ehrenfest DM, Rasmusson L, Albrektsson T (2009) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 27:158–167. doi: 10.1016/j.tibtech.2008.11.009 CrossRefPubMedGoogle Scholar
  25. 25.
    Wasterlain AS, Braun HJ, Dragoo JL (2012) Contents and formulations of platelet-rich plasma. Oper Tech Orthop 22:33–42. doi: 10.1053/j.oto.2011.11.001 CrossRefGoogle Scholar
  26. 26.
    Cavallo C, Filardo G, Mariani E et al (2014) Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Jt Surg Am 96:423–429. doi: 10.2106/JBJS.M.00726 CrossRefGoogle Scholar
  27. 27.
    Filardo G, Kon E, Pereira Ruiz MT et al (2012) Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sport Traumatol Arthrosc 20:2082–2091. doi: 10.1007/s00167-011-1837-x CrossRefGoogle Scholar
  28. 28.
    Riboh JC, Saltzman BM, Yanke AB et al (2016) Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med 44:792–800. doi: 10.1177/0363546515580787 CrossRefPubMedGoogle Scholar
  29. 29.
    Meheux CJ, McCulloch PC, Lintner DM et al (2016) Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthrosc J Arthrosc Relat Surg 32:495–505. doi: 10.1016/j.arthro.2015.08.005 CrossRefGoogle Scholar
  30. 30.
    Napolitano M, Matera S, Bossio M et al (2012) Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. Blood Transfus 10:72–77. doi: 10.2450/2011.0026-11 PubMedPubMedCentralGoogle Scholar
  31. 31.
    Jang SJ, Do Kim J, Cha SS (2013) Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis. Eur J Orthop Surg Traumatol 23:573–580. doi: 10.1007/s00590-012-1037-5 CrossRefPubMedGoogle Scholar
  32. 32.
    Kon E, Mandelbaum B, Buda R et al (2011) Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. J Arthrosc Relat Surg 27:1490–1501. doi: 10.1016/j.arthro.2011.05.011 CrossRefGoogle Scholar
  33. 33.
    Sampson S, Reed M, Silvers H et al (2010) Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 89:961–969. doi: 10.1097/PHM.0b013e3181fc7edf CrossRefPubMedGoogle Scholar
  34. 34.
    Cerza F, Carní S, Carcangiu A et al (2012) Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 40:2822–2827. doi: 10.1177/0363546512461902 CrossRefPubMedGoogle Scholar
  35. 35.
    Sánchez M, Fiz N, Azofra J et al (2012) A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. J Arthrosc Relat Surg 28:1070–1078. doi: 10.1016/j.arthro.2012.05.011 CrossRefGoogle Scholar
  36. 36.
    Vaquerizo V, Plasencia MA, Arribas I et al (2013) Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. J Arthrosc Relat Surg 29:1635–1643. doi: 10.1016/j.arthro.2013.07.264 CrossRefGoogle Scholar
  37. 37.
    Laudy ABM, Bakker EWP, Rekers M, Moen MH (2015) Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med 49:657–672. doi: 10.1136/bjsports-2014-094036 CrossRefPubMedGoogle Scholar
  38. 38.
    Kanchanatawan W, Arirachakaran A, Chaijenkij K et al (2015) Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee. Knee Surg Sport Traumatol Arthrosc 24:1665–1677. doi: 10.1007/s00167-015-3784-4 CrossRefGoogle Scholar
  39. 39.
    Filardo G, Kon E, Di Martino A et al (2012) Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 13:229. doi: 10.1186/1471-2474-13-229 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Bannuru RR, Dasi UR, McAlindon TE (2010) Reassessing the role of acetaminophen in osteoarthritis: systematic review and meta-analysis. Osteoarthr Cartil 18:S250. doi: 10.1016/S1063-4584(10)60585-7 CrossRefGoogle Scholar
  41. 41.
    AAOS (2013) Treatment of osteoarthritis of the knee evidence-based guideline, 2nd edn. Am Acad Orthop Surg, Board DirGoogle Scholar
  42. 42.
    Miceli-Richard C, Le Bars M, Schmidely N, Dougados M (2004) Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 63:923–930. doi: 10.1136/ard.2003.017236 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Richette P, Latourte A, Frazier A (2015) Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? Expert Opin Drug Saf 14:1259–1268. doi: 10.1517/14740338.2015.1056776 CrossRefPubMedGoogle Scholar
  44. 44.
    Matuska A, O’Shaughnessey K, King W, Woodell-May J (2013) Autologous solution protects bovine cartilage explants from IL-1β- and TNFα-induced cartilage degradation. J Orthop Res 31:1929–1935. doi: 10.1002/jor.22464 CrossRefPubMedGoogle Scholar
  45. 45.
    Burger D, Dayer JM, Palmer G, Gabay C (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20:879–896. doi: 10.1016/j.berh.2006.06.004 CrossRefPubMedGoogle Scholar
  46. 46.
    Kokebie R, Aggarwal R, Lidder S et al (2011) The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis Res Ther 13:R50. doi: 10.1186/ar3293 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ng KW, O’Conor CJ, Kugler LE et al (2011) Transient supplementation of anabolic growth factors rapidly stimulates matrix synthesis in engineered cartilage. Ann Biomed Eng 39:2491–2500. doi: 10.1007/s10439-011-0356-8 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Deepthi S, Jayakumar R (2016) Prolonged release of TGF-β from polyelectrolyte nanoparticle loaded macroporous chitin-poly(caprolactone) scaffold for chondrogenesis. Int J Biol Macromol. doi: 10.1016/j.ijbiomac.2016.03.068 Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Mario Simental-Mendía
    • 1
  • José F. Vílchez-Cavazos
    • 2
  • Víctor M. Peña-Martínez
    • 2
  • Salvador Said-Fernández
    • 1
  • Jorge Lara-Arias
    • 2
  • Herminia Guadalupe Martínez-Rodríguez
    • 1
    Email author
  1. 1.Department of Biochemistry and Molecular Medicine, Faculty of MedicineAutonomous University of Nuevo León (UANL)MonterreyMéxico
  2. 2.Department of Orthopaedics and Traumatology, University HospitalUANLMonterreyMéxico

Personalised recommendations